WO2016193456A3 - Antagoniste de récepteur d'opioïde destiné à être utilisé dans le traitement de patients souffrant de constipation sévère - Google Patents

Antagoniste de récepteur d'opioïde destiné à être utilisé dans le traitement de patients souffrant de constipation sévère Download PDF

Info

Publication number
WO2016193456A3
WO2016193456A3 PCT/EP2016/062692 EP2016062692W WO2016193456A3 WO 2016193456 A3 WO2016193456 A3 WO 2016193456A3 EP 2016062692 W EP2016062692 W EP 2016062692W WO 2016193456 A3 WO2016193456 A3 WO 2016193456A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonist
opioid receptor
treating patients
opioid
severe constipation
Prior art date
Application number
PCT/EP2016/062692
Other languages
English (en)
Other versions
WO2016193456A2 (fr
Inventor
Hélène Rey
Olaf MUNDSZINGER
Isabelle GOLFIER
Silvia JAKOB
Oliver RUSCH
Marc Fischer
Christian Holl
Original Assignee
Develco Pharma Schweiz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develco Pharma Schweiz Ag filed Critical Develco Pharma Schweiz Ag
Priority to EP16730722.2A priority Critical patent/EP3302476A2/fr
Publication of WO2016193456A2 publication Critical patent/WO2016193456A2/fr
Publication of WO2016193456A3 publication Critical patent/WO2016193456A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Abstract

La présente invention concerne une composition pharmaceutique comprenant un antagoniste de récepteur d'opioïde, ou un dérivé ou un sel pharmaceutiquement acceptable de celui-ci, en tant que substance active, laquelle composition libère la substance active de manière prolongée. La composition convient à une période d'administration d'au moins douze heures pour le traitement d'une constipation sévère induite par un opioïde chez des patients recevant une dose quotidienne d'opioïde équivalente à au moins 80 mg de morphine.
PCT/EP2016/062692 2015-06-03 2016-06-03 Antagoniste de récepteur d'opioïde destiné à être utilisé dans le traitement de patients souffrant de constipation sévère WO2016193456A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP16730722.2A EP3302476A2 (fr) 2015-06-03 2016-06-03 Antagoniste de récepteur d'opioïde destiné à être utilisé dans le traitement de patients souffrant de constipation sévère

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15170570 2015-06-03
EPEP15170570.4 2015-06-03
EPEP15170566.2 2015-06-03
EP15170566 2015-06-03

Publications (2)

Publication Number Publication Date
WO2016193456A2 WO2016193456A2 (fr) 2016-12-08
WO2016193456A3 true WO2016193456A3 (fr) 2017-01-12

Family

ID=56148357

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/062692 WO2016193456A2 (fr) 2015-06-03 2016-06-03 Antagoniste de récepteur d'opioïde destiné à être utilisé dans le traitement de patients souffrant de constipation sévère

Country Status (1)

Country Link
WO (1) WO2016193456A2 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032180A2 (fr) * 1999-11-01 2001-05-10 Rodeva Limited Composition destinee au traitement de la constipation et du syndrome du colon irritable
WO2004091622A1 (fr) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Utilisation d'antagonistes des opioides peripheriques, en particulier de methylnaltrexone, dans le traitement du syndrome du colon irritable
WO2004091665A1 (fr) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Traitement combine de la constipation comprenant un laxatif et un antagoniste des opioides a action peripherique
WO2005107726A2 (fr) * 2004-04-27 2005-11-17 Pain Therapeutics, Inc. Procede pour le traitement de mal de dos
EP1695700A1 (fr) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Forme posologique contenant de l'oxycodone et de la naloxone
WO2006127899A2 (fr) * 2005-05-25 2006-11-30 Progenics Pharmaceuticals, Inc. Synthese de (r)-n-methylnaltrexone
US20100221339A1 (en) * 2006-01-19 2010-09-02 Phoenux Ag Use of a combination of morphine and at least one opiate antagonist to treat opiate dependency and prevent non-oral opiate abuse among opiate addicts
WO2015071380A1 (fr) * 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone et naloxone utilisées pour le traitement de la douleur et du syndrome de dysfonctionnement intestinal dû aux opioïdes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
IT1398930B1 (it) 2010-03-24 2013-03-28 Molteni & C Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032180A2 (fr) * 1999-11-01 2001-05-10 Rodeva Limited Composition destinee au traitement de la constipation et du syndrome du colon irritable
WO2004091622A1 (fr) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Utilisation d'antagonistes des opioides peripheriques, en particulier de methylnaltrexone, dans le traitement du syndrome du colon irritable
WO2004091665A1 (fr) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Traitement combine de la constipation comprenant un laxatif et un antagoniste des opioides a action peripherique
WO2005107726A2 (fr) * 2004-04-27 2005-11-17 Pain Therapeutics, Inc. Procede pour le traitement de mal de dos
EP1695700A1 (fr) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Forme posologique contenant de l'oxycodone et de la naloxone
WO2006127899A2 (fr) * 2005-05-25 2006-11-30 Progenics Pharmaceuticals, Inc. Synthese de (r)-n-methylnaltrexone
US20100221339A1 (en) * 2006-01-19 2010-09-02 Phoenux Ag Use of a combination of morphine and at least one opiate antagonist to treat opiate dependency and prevent non-oral opiate abuse among opiate addicts
WO2015071380A1 (fr) * 2013-11-13 2015-05-21 Euro-Celtique S.A. Hydromorphone et naloxone utilisées pour le traitement de la douleur et du syndrome de dysfonctionnement intestinal dû aux opioïdes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JURNA I ET AL: "Retardiert freigesetztes Naloxon oral: Aufhebung der Obstipation durch orales Morphin ohne Beseitigung der Analgesie. [Oral administration of slow-release naloxone for prevention of constipation but not analgesia following oral morphine.]", SCHMERZ, DER, SPRINGER VERLAG, BERLIN, DE, vol. 7, no. 4, 1 December 1993 (1993-12-01), pages 314 - 321, XP009176556, ISSN: 0932-433X *

Also Published As

Publication number Publication date
WO2016193456A2 (fr) 2016-12-08

Similar Documents

Publication Publication Date Title
HRP20200600T1 (hr) Tapentadol za sprječavanje i liječenje depresije i tjeskobe
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
WO2014205229A8 (fr) Utilisation de pridopidine à forte dose pour traiter la maladie de huntington
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
WO2011157416A3 (fr) Administration transdermique de mémantine
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
AR074240A1 (es) Compuesto 3-(4-cloro-2-fluorobencil )-2-metil-n-(5- metil-1h- pirazol-3-il)-8- (morfolinometil)imidazo (1,2-b)piridazin -6-amina o una sal farmaceuticamente aceptable del mismo, su uso para preparar un medicamento util para el tratamiento de trastornos mieloproliferantes cronicos y condiciones asoci
PH12016500666A1 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
WO2018027084A3 (fr) Combinaison d'antagonistes de récepteur du glucagon et d'inhibiteurs de la voie pi3k pour le traitement du cancer
WO2007145863A3 (fr) Formulation à libération prolongée de naltréxone
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
TN2019000063A1 (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
RU2010154623A (ru) Производные 1-аминоалкилциклогексана для лечения расстройств сна
WO2016193456A3 (fr) Antagoniste de récepteur d'opioïde destiné à être utilisé dans le traitement de patients souffrant de constipation sévère
JP2016528283A5 (fr)
BR112012020415A2 (pt) composição farmacêutica para a prevenção ou tratamento da osteoartrite
WO2020013776A3 (fr) Effet synergique du naproxène et un agent protecteur gatrique qui traite la douleur et l'inflammation
WO2016193454A3 (fr) Dosage de la naloxone
WO2018231176A3 (fr) Combinaisons de diclofénac et d'antagonistes du récepteur h2 pour le traitement de la douleur et de l'inflammation
PH12016502540A1 (en) Pharmaceutical dosage forms
EA201590760A1 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции
EA201991384A1 (ru) Комбинации диклофенака и антагонистов h2-рецептора для лечения боли и воспаления
RU2019109965A (ru) Лекарственное средство, эффективное для лимфогенного способа введения лекарственного средства

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16730722

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016730722

Country of ref document: EP